SAM
CERE

Stansberry Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Stansberry Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-281,694
Closed -$11.5M – 131
2024
Q2 		$11.5M Buy
281,694
+91,906
+48% +$3.83M 1.51% 23
2024
Q1 		$8.02M Buy
+189,788
New +$7.97M 1.08% 34

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Stansberry Asset Management's CERE Position: Q3 2024 in Review

Stansberry Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 281,694 shares — an estimated $11.5M sold.

Stansberry Asset Management first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $11.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Stansberry Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Stansberry Asset Management sold 281,694 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11.5M.
  • Stansberry Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Stansberry Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Stansberry Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.